1cP-MiPLA Stats & Data

1cP‑MiPLA is a 1‑cyclopropionyl‑substituted lysergamide; by analogy to 1‑acyl LSD analogues, it is expected to hydrolyze in vivo to MiPLA and act primarily as a prodrug. Direct human pharmacokinetics are uncharacterized; assume delayed onset vs. parent amide and plan set/setting accordingly. Potency appears materially lower than LSD and highly product‑dependent; multiple user datasets report weak or threshold effects at 200 \u0000b5g and full effects at 300–800 \u0000b0g, highlighting the need to start low and titrate. Reagent tests: Ehrlich/Hofmann can ‘rule‑in’ an indole/lysergamide but cannot confirm identity or dose; only LC/MS‑based drug checking can. Some market blotters labeled as 1cP‑MiPLA have tested impure (e.g., significant iso‑isomers and unidentified byproducts), potentially reducing expected potency and altering side‑effect profile. Lysergamides produce rapid, pronounced acute tolerance—redosing after the first hour generally adds side‑effects and duration more than intensity. Like LSD, risks include anxiety/panic, vasoconstriction, hyperthermia in strenuous settings, and insomnia; a sober sitter, hydration, and temperature management reduce complication risk. Avoid if you have a history of psychosis or bipolar I; defer use during pregnancy. Leave at least 14 days between serotonergic psychedelic sessions to minimize tolerance stacking and potential HPPD risk. Never drive or engage in hazardous activities until fully baseline (often the next day).